TRANCE, also known as receptor activator of nuclear factor-κB ligand (RANKL), is a member of the tumor necrosis factor superfamily, recognized for its significant role in bone development and various bone disorders, including osteoporosis, Paget’s disease, and metastatic bone cancer [22, 23]. Here, TNFSF11 is linked to bone disorder.